Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. METHODS: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). RESULTS: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. CONCLUSIONS: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subset of those suffering from Major Depressive Disorder (MDD) achieve remission with antidepressant medication (ADM)1.”
From The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse (2020) · cites this paper as [1]
In the citing paper
“about onethird receive no benefit from two or more pharmacologic treatments (Rush et al., 2006;Trivedi et al., 2006).”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Rush et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationCUMULATIVE ILLNESS RATING SCALE
LINN, B. S., LINN, M. W., & GUREL, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,304
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationAgency for Health Care Policy and Research
Eisenberg, J. M. (1999) · Medical Care · doi:10.1097/00005650-199903000-00001 · Cited by 1,369
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citation
Research works printed but not linked: 4
- Agency for Health Care Policy and Research. Depression in primary care. Vol. 2. Treatment of major depression. Rockville, Md.: Department of Health and Human Services, 1993. (AHCPR publication no. 93-0551.)
- Fava M, 2000, J Clin Psychiatry, 61, 10
- Joffe RT, 1996, J Clin Psychiatry, 57, 114
- Fava M, 2003, Ann Clin Psychiatry, 15, 17, 10.3109/10401230309085666 · doi:10.3109/10401230309085666 · Paper page
Cited by
Items 801–900 of 999
Holsboer‐Trachsler, E., & Holsboer, F. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_53 · Cited by 2
Kunugi, H., & Tikhonova, M. A. (2022) · Progress in brain research · doi:10.1016/bs.pbr.2022.01.023 · Cited by 2
Preskorn, S. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000358316.96555.f2 · Cited by 2
Demitrack, M. A. (2010) · Psychopharm Review · doi:10.1097/01.idt.0000384050.93852.3e · Cited by 2
Pharmacological treatment approaches to difficult-to-treat depression
Chan, H., Mitchell, P. B., Loo, C. K. A., & Harvey, S. B. (2012) · The Medical Journal of Australia · doi:10.5694/mjao12.10495 · Cited by 2
What We Learn About Continuation Treatments From the Collaborative Electroconvulsive Therapy Studies
Fink, M. (2007) · Journal of Ect · doi:10.1097/yct.0b013e31814da984 · Cited by 3
“They also compare favorably with the 30% remission with citalopram and the 18%, 21%, and 25% reductions after bupropion, sertraline, and venlafaxine in the STAR*D study of patients with nonpsychotic major depression.(7) How stable is the remission after 1 week? In the CUC study, of 159 remitters, 17 developed sufficie…”
ResultMarić, N. P., Pekić, S., Doknic, M., Jašović‐Gašić, M., Zivkovic, V., Stojanović, M., Djurovic, B., & POPOVIC, V. M. (2007) · Hormone Research in Paediatrics · doi:10.1159/000097577 · Cited by 2
How Do You Choose a Second-Line Treatment Option for Depression?
Weisler, R. H. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9104su1c.04 · Cited by 2
Impact of the STAR*D Trial From the Perspective of the Payer
Little, A. A., Hansen, R. A., Gartlehner, G., & Gray, C. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1463 · Cited by 2
Ivanets, N. N., Kinkulkina, M. A., Avdeeva, T. I., Tikhonova, Y. G., & Luk'ianova, A. V. (2016) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20161165143-51 · Cited by 2
Applicability of network perspectives of psychopathology: To promote tailored therapy for depression
Kashihara, J. (2019) · doi:10.24602/sjpr.62.2_143 · Cited by 3
Pharmacological Management of Treatment‐Resistant Unipolar Depression
McGrath, P. J., & Miller, J. M. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch112 · Cited by 2
Zukunftsstrategien für die Entdeckung neuer Antidepressiva
Holsboer, F. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_9 · Cited by 2
Commentary on STAR*D: a summary and UK perspective
Anderson, I. M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109104888 · Cited by 2
Combination Antidepressants are not yet Proven Therapy in the Treatment of Depression
Olver, J. S., Ellen, S., & Norman, T. R. (2007) · Australasian Psychiatry · doi:10.1080/10398560701354930 · Cited by 2
Treatment of Depression in Patients With Coronary Artery Disease—Reply
Lespérance, F., & Frasure‐Smith, N. (2007) · JAMA · doi:10.1001/jama.297.17.1880-a · Cited by 2
Release bias in accessing medical records in clinical trials: a STAR*D report
Kashner, T. M., Trivedi, M. H., Wicker, A. B., Fava, M., Shores-Wilson, K., Wisniewski, S., & Rush, A. (2009) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.286 · Cited by 2
“Data collection As described elsewhere (Fava et al., 2003; Rush et al., 2004; Rush et al., 2006b; Trivedi et al., 2006a; Trivedi et al., 2006b), demographic, education, earnings, employment, and health insurance information were collected at baseline from face-to-face and telephone interviews with…”
MethodSelf-citationSecond-Generation Antidepressants
Gebhart, G. F., & Schmidt, R. F. (2013) · Springer eBooks · doi:10.1007/978-3-642-28753-4_102073 · Cited by 2
Specific Mental Health Disorders: Depressive and Anxiety Disorders
Hickie, I. B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803678-5.00425-2 · Cited by 2
Electroconvulsive Therapy—An Outdated Treatment, or One Whose Time Has Come?
Kimball, J. N. (2007) · Southern Medical Journal · doi:10.1097/smj.0b013e318046f8c1 · Cited by 2
Thyroid Function and Depression
Jørgensen, M. B., & Feldt‐Rasmussen, U. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.96001-x · Cited by 2
Xu, C., Kim, T. T., Kirsch, I., Plöderl, M., Amsterdam, J. D., & Pigott, H. E. (2025) · medRxiv · doi:10.1101/2025.02.10.25321991 · Cited by 2
Antidepressant Augmentation: Good News, Limitations, and Stumbling Blocks: (Commentary)
Kocsis, J. H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14com09536 · Cited by 1
Two rTMS sessions per week: a practical approach for treating major depressive disorder
Armas-Castañeda, G., Ricardo-Garcell, J., López, J. V. R., Heinze, G., Salín, R. J., & González, J. J. (2021) · Neuroreport · doi:10.1097/wnr.0000000000001737 · Cited by 8
Chapter 20. Psychopharmacology
Mulsant, B. H., & Pollock, B. G. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375196.ds20 · Cited by 1
Current Pharmacotherapies for Smoking Cessation and Promising Emerging Drugs
Dodd, S., Harper, J., & Berk, M. (2023) · Current Clinical Pharmacology · doi:10.2174/0127724328274939231121114142 · Cited by 2
Pavlova, T. A., Telepina, M. A., Perelygin, V. V., Smetannikova, E. A., Sklyarova, N. A., & Orlova, A. V. (2025) · Pharmacy Formulas · doi:10.17816/phf686915 · Cited by 3
Burkhardt, G., Goerigk, S. A., Bulubas, L., Dechantsreiter, E., Keeser, D., Vogelmann, U., von Wartensleben, K., Wolf, J., Plewnia, C., Fallgatter, A. J., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111600 · Cited by 5
Buchbauer, H., Adli, M., Schlattmann, P., Berger, M., Bschor, T., Stamm, T., Behr, J., Ricken, R., & Buspavanich, P. (2026) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.70127 · Cited by 2
Park, Y., Lenk, H. Ç., Zhou, Y., Lauschke, V. M., & Molden, E. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00238-5 · Cited by 1
Dar, M. A., & Wani, R. A. (2015) · International Journal of Emergency Mental Health and Human Resilience · doi:10.4172/1522-4821.1000209 · Cited by 1
“The STAR*D (Sequenced Treatment Alternatives to Relieve Depression) treatment, the gold standard trial showed an average response rate of 47% and remission rates of around 30% for patients treated in 23 psychiatric and 18 primary care settings (Trivedi et al., 2006).”
BackgroundResultJust How Effective are Antidepressant Medications? Results of a Major New Study
Boren, J. J., Leventhal, A., & Pigott, H. (2009) · Journal of Contemporary Psychotherapy · doi:10.1007/s10879-008-9095-z · Cited by 2
“A later paper in the STAR*D series summarizing follow-up results (Rush et al. 2006a) revealed that 795 mildly depressed patients had also been treated.”
BackgroundMethodInfluentialTreating depression and achieving remission
Narasimhan, M., & Kannaday, M. H. (2010) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2010.10.004 · Cited by 1
Thase, M. E. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0072-8 · Cited by 1
Self-citationMartínez-Granados, F., Climent‐Grana, E., Pérez-Martínez, E., Baines, J. P. O., Otaolaurruchi, J. S., & Martinez, M. Á. B. (2011) · Farmacia Hospitalaria · doi:10.1016/j.farma.2010.06.003 · Cited by 1
Developments in Psychopharmacology for Major Depressive Disorder
Chang, T. E., & Stahl, S. M. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.4.452 · Cited by 1
THE ASSOCIATION OF DIABETES MELLITUS WITH RESPONSE TO DEPRESSION TREATMENT
Bryan, C. J. (2006) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Assessing a Therapeutic Exchange Protocol for Second-generation Antidepressants: Clinical Results
Martínez-Granados, F., Climent‐Grana, E., Pérez-Martínez, E., Baines, J. P. O., Otaolaurruchi, J. S., & Martinez, M. Á. B. (2011) · Farmacia Hospitalaria (English Edition) · doi:10.1016/j.farmae.2010.06.007 · Cited by 1
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Stein, D. J., & Versiani, M. (2011) · Cited by 1
Introduction: Selecting an Antidepressant
Zimmerman, M. A. (2009) · CNS Spectrums · doi:10.1017/s1092852900026341 · Cited by 1
Reward Processing in Motivational and Affective Disorders
Skandali, N. (2016) · Frontiers research topics · doi:10.3389/978-2-88919-986-0 · Cited by 1
Burns, R. B., Smetana, G. W., & Brady, R. O. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0966 · Cited by 1
Strategies and Solutions for Switching Antidepressant Medications
Soreide, K. K., Ward, K. M., PharmD, Bostwick, J. R., Bcps, & Bcpp (2017) · Cited by 1
Melancholia: Beyond DSM, Beyond Neurotransmitters, May 2–4, 2006, Copenhagen Marriott
(2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.00972.x · Cited by 3
“Half the patients were not relieved in the repeated trials (1).”
BackgroundCombining Medications to Achieve Remission
Zajecka, J., & Goldstein, C. (2009) · Medical psychiatry · doi:10.3109/9781420084887.003 · Cited by 2
Aripiprazole as First-Line Therapy for Late-Life Depression
Sonal, A., & Srivastava, S. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001530 · Cited by 1
Adu, M. K., Dias, R. D. L., Agyapong, B., Eboreime, E., Sapara, A. O., Lawal, M. A., Chew, C., Frost, K. D., Li, D., Flynn, M., et al. (2023) · JMIR Research Protocols · doi:10.2196/46830 · Cited by 1
“Data demonstrate that among MDD patients who receive first-line treatment, about 50% fail to achieve remission, with two-thirds requiring further treatment trials before they can reach the state of remission [9,10].”
Bhachech, H., Nath, K., Sidana, R., Shah, N., Nagpal, R., Sathianathan, R., Kakkad, A., & Korukonda, K. (2024) · Cureus · doi:10.7759/cureus.52878 · Cited by 1
“The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial demonstrated that bupropion substitution or augmentation was equally or more effective than alternative approaches [17,18].”
BackgroundModulation of gut microbiota in the therapy of mental disorders – new therapeutic strategies
Bystron, J. M., & Dziekiewicz, A. (2024) · Environmental Medicine · doi:10.26444/ms/187949 · Cited by 1
“Clinical studies have shown that a significant percentage of patients with severe depressive disorders – Major Depressive Disorder (MDD) – do not respond to currently used first-line antidepressant treatments or do not achieve remission [10, 19].”
BackgroundAdu, M. K., Eboreime, O., Shalaby, R., Eboreime, E., Agyapong, B., Dias, R. D. L., Sapara, A. O., & Agyapong, V. I. O. (2024) · JMIR Formative Research · doi:10.2196/59003 · Cited by 2
“Data suggest that, despite the robust first-line treatment available for individuals diagnosed with MDD, about 50% of these patients do not attain remission, with two-thirds requiring additional treatment attempts before achieving remission [7,8].”
Schreyer, L., Kalocsai, C., Fernando, O., Anderson, M., Lockwood, V., Soklaridis, S., Remington, G. J., Chintoh, A. F., & Berkhout, S. (2024) · SSM - Mental Health · doi:10.1016/j.ssmmh.2024.100350 · Cited by 1
Tan, X.-C., Joyce, Y. Y. C., Lim, Y.-J., Frederick, P. K., Jovi, Z. J. K., Hasvinjit, G. S. K., Rachel, S., Zhong, L., & Tor, P. (2025) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2025.100935 · Cited by 1
Aging, inflammation and depressive behavior: a review
Uzoni, A., Ciobanu, O., Sandu, R. E., Bugă, A. M., & Popa‐Wagner, A. (2015) · Reviews in Health Care · doi:10.7175/rhc.v6i2.1170 · Cited by 1
“Despite advances in the treatment of major depression, one-third of depressed patients fail to respond to conventional antidepressant medication [33].”
BackgroundEasing the Burden of Treatment-Resistant Depression
Fava, M., Nelson, J. C., Thase, M. E., & Trivedi, M. H. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.bm8017ah1c · Cited by 2
“Those switched to venlafaxine experienced a nonsignificantly greater remission rate compared with those taking bupropion or sertraline according to the 17-item Hamilton Rating Scale for Depression (HAMD-17), but QIDS-SR scores showed almost identical remission rates for all 3 groups.(34) In the third treatment stage o…”
ResultSelf-citationFleck, M. P., Moreno, R. A., de Andrade, A. G., Bottino, C. M. C., & Kerr-Corrêa, F. (2010) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832010000600001 · Cited by 2
“Uma diferença importante é que nossa amostra possuía um escore HAM-D na linha de base de 27 (7,2), comparada com 18,9 (7,3) no nível 2 do estudo STAR*D.”
BackgroundManagement of major depressive disorder in primary care.
Dantz, B. (2008) · PubMed · Cited by 1
Jackson, E., & Endow-Eyer, R. A. (2014) · Mental Health Clinician · doi:10.9740/mhc.n207175 · Cited by 1
“Response and remission rates decrease even further with each successive medication trial.(3-4)”
BackgroundDepresyon Tedavisinde Karşılanmamış İhtiyaçlar: Eştanılı Anksiyete ve Yaklaşım
Dılbaz, N., Darçın, A. E., & Çavuş, S. Y. (2011) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.1080/10177833.2011.11790744 · Cited by 4
A Physiological Marriage Made in Heaven: Treating and Measuring the Brain Through Stimulation
Daskalakis, Z. J., & Tyndale, R. F. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1576 · Cited by 1
“About a third of patients with depression fail to respond to antidepressant treatments.(1) In the United States, the population of patients estimated to be experiencing treatment-resistant depression (TRD) is about 8 million per year.”
BackgroundPharmacogenomics in Older Adults: An Integrative Review
Inventor, B. R., & Paun, O. (2021) · Research in Gerontological Nursing · doi:10.3928/19404921-20210428-01 · Cited by 1
Estimulação magnética transcraniana: o que o psiquiatra deve saber?
Montenegro, M. C., & Cantilino, A. (2016) · Debates em Psiquiatria · doi:10.25118/2763-9037.2016.v6.131 · Cited by 1
The use of vitamin D in depression
Lange, K. W., Lange, K. M., Nakamura, Y., & Reißmann, A. (2021) · Journal of Food Bioactives · doi:10.31665/jfb.2021.15278 · Cited by 1
“Almost a third of people treated for depression remain refractory to multistep antidepressant therapies (Rush et al., 2006a; Rush et al., 2006b), and the long-term effectiveness of pharmacotherapy and psychotherapy remains a matter of debate (Casacalenda et al.”
BackgroundOutcomes in the Treatment of Major Depressive Disorder
Thase, M. E., & Koenig, A. M. (2009) · Medical psychiatry · doi:10.3109/9781420084887.002 · Cited by 1
Self-citationMuit, J. J., van Eijndhoven, P., Cipriani, A., Dalhuisen, I., van Bronswijk, S. C., Furukawa, T. A., & Ruhé, H. G. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-056777 · Cited by 2
Karimi, I., Yakhchalian, N., Fathi, M., & Miraghaee, S. (2022) · Universal Journal of Pharmaceutical Research · doi:10.22270/ujpr.v7i3.779 · Cited by 4
Combination Therapies and Switching of Agents in Depression and Bipolar Disorders
Folsche, T., Maier, H. B., Hillemacher, T., & Frieling, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_437 · Cited by 1
Chronische und therapieresistente Depression (ICD-10 F3)
Schramm, E., & BAUER, M. (2008) · Elsevier eBooks · doi:10.1016/b978-343724780-4.50012-9 · Cited by 1
Remisson in depression – is it a realistic goal?
Karlsson, H. (2008) · Nordic Journal of Psychiatry · doi:10.1080/08039480802601429 · Cited by 1
Commentary on STAR*D: a summary and UK perspective
McAllister-Williams, H. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109104889 · Cited by 1
Tamayo, J. M., Rosales-Barrera, J. I., Villaseñor-Bayardo, S. J., & Rojas-Malpica, C. (2011) · Salud Mental · Cited by 4
Management of Depression Associated with HIV/AIDS and Antiretrovial Therapy
Halman, M. H. (2006) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2006/254238 · Cited by 1
Long, T. C. (2008) · PubMed · Cited by 2
Moffa, A. H. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.47.2016.tde-07102016-180727 · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Specific Mental Health Disorders: Depressive and Anxiety Disorders
Hickie, I. B. (2008) · Elsevier eBooks · doi:10.1016/b978-012373960-5.00048-4 · Cited by 1
Morrison, A., & Weston, C. G. (2012) · Wiley eBooks · doi:10.1002/9781119945925.ch7 · Cited by 1
Xu, C., Kim, T. T., Plöderl, M., Kennedy, K. P., Kirsch, I., Amsterdam, J. D., & Pigott, H. E. (2025) · medRxiv · doi:10.1101/2025.10.27.25338365 · Cited by 1
Pontén, E. (2015) · Örebro University Library (Örebro University) · Cited by 1
N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression
Skolnick, P., Popik, P., & Trullás, R. (2010) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0346-0241-9_1 · Cited by 2
“For example, in an NIH sponsored study [ 13 ] of depressed patients who had no symptom remission following an SSRI, Rush et al. reported a remission rate of � 25% following a second, biogenic aminebased agent, with the remaining cohort apparently treatment resistant.”
BackgroundTackling Partial Response to Depression Treatment
Thase, M. E., Gaynes, B. N., Papakostas, G. I., Shelton, R. C., & Trivedi, M. H. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.8133ah3c · Cited by 3
Schwertfeger, N., Regen, F., Szegedi, A., & Benkert, O. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_76
CNS drug development – Phase III
Dunn, J. A., Randall, P., & Kalali, A. H. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977640.007
Chronische und therapieresistente Depressionen (ICD-10 F3)
Schramm, E., & Bauer, M. (2009) · Elsevier eBooks · doi:10.1016/b978-3-437-24900-6.50012-5
McGrath, P. J., & Roose, S. P. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.004
The Nature and Treatment of Therapy-Resistant Depression
Kennedy, S., Rizvi, S., & Giacobbe, P. (2010) · Modern trends in psychiatry · doi:10.1159/000319516
The silver lining of recent effectiveness trials
Schatzberg, A. F. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00203.x
“This was an unfortunate consequence of STAR*D, where Phase II inpatients could themselves choose to switch to a new agent or augment with the addition of a second one (1,2).”
BackgroundEvidenzbasierung und leitliniengestützte Therapie in der Psychiatrie
Möller, H. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_43
Antidepressant Combination Strategies for Major Depressive Disorder
Carvalho, A. F., Macêdo, D. S., Hyphantis, T. N., & McIntyre, R. S. (2012) · Springer eBooks · doi:10.1007/978-94-007-5799-8_10
Casher, M. I., & Bess, J. D. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511933783.004
Fandiño-Losada, C. A. (2013) · Figshare
AlRuthia, Y. S., & Hong, S. H. (2014) · Journal of Pharmaceutical Health Services Research · doi:10.1111/jphs.12049
Een serotonineheropnameremmer werkt niet voldoende bij depressie. En nu?
Sitsen, J. M. A. (2006) · Medisch-Farmaceutische Mededelingen · doi:10.1007/bf03058823
McClure, R. K. (2014) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2014.01.00013
“Of note, the response rate of MDD for any single antidepressant class is also quite low [21].”
BackgroundThe Role of Bupropion in the Management of Major Depressive Disorder
Ha, K., Tawadros, Y., & IsHak, W. W. (2011) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s20
O’Reardon, J. P., Groff, K. E., Stunkard, A. J., & Allison, K. C. (2007) · Progress in Neurotherapeutics and Neuropsychopharmacology · doi:10.1017/s1748232107000067
Barondes, S. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmbkrev57417
Dynamics of drug evaluation: Formulary placement of antipsychotics
Mascareñas, C. A., & Oliveira, R. (2013) · Mental Health Clinician · doi:10.9740/mhc.n172348
Improving the clinical effectiveness of antidepressant treatment
Kennedy, S. H. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.044
Collins, H. E. (2010) · UTAS Research Repository · doi:10.25959/23208680
Ehret, M. J., & Chavez, B. (2006) · Journal of Pharmacy Practice · doi:10.1177/0897190007300736
“In the level 2 switch study, 727 patients were randomly assigned to switch from citalopram to either sustained-release bupropion (n = 239), sertraline (n = 238), or venlafaxine XR (n = 250).(20) The dosing schedule was flexible, with a recommended final dose of bupropion 400 mg, sertraline 200 mg, and venlafaxine XR 3…”
Background
Metadata
- Authors
- Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., Shores-Wilson, K., Niederehe, G., & Fava, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- New York State Psychiatric Institute (US)
- Massachusetts General Hospital (US)
- National Institute of Mental Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1231-1242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140787893
- Cited by
- 1,033
- References
- 44
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 28 · 2021: 46 · 2020: 43 · 2019: 54 · 2018: 51 · 2017: 35 · 2016: 42 · 2015: 45 · 2014: 46 · 2013: 45 · 2012: 43
- FWCI
- 66.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, antidepressant switching, bupropion, sertraline, venlafaxine, treatment-resistant depression, symptom remission, antidepressant response, outpatients
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Remission Induction, Time Factors, Bupropion, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.